| Literature DB >> 30344182 |
Anne F Klassen1, Manraj Kaur1, Natasha Johnson1, Baudewijntje Pc Kreukels2, Giancarlo McEvenue3, Shane D Morrison4, Margriet G Mullender5, Lotte Poulsen6, Mujde Ozer5, Will Rowe1, Thomas Satterwhite7, Kinusan Savard8, John Semple9, Jens Ahm Sørensen6, Tim C van de Grift5, Maeghan van der Meij-Ross5, Danny Young-Afat10, Andrea L Pusic11.
Abstract
INTRODUCTION: A critical barrier to outcome assessment in gender-affirming healthcare is the lack of a specific patient-reported outcome measure (PROM). This phase I protocol describes an international collaboration between investigators in Canada, Denmark, the Netherlands and the USA who have coalesced to develop a new PROM (ie, the GENDER-Q) to evaluate outcomes of psychological, hormonal and surgical gender-affirming treatments. METHODS AND ANALYSIS: This phase I study uses an interpretive description approach. Participants aged 16 years and older seeking any form of gender-affirming treatments in centres located in Canada, Denmark, the Netherlands and the USA will be invited to take part in qualitative interviews. Participants will review BREAST-Q and FACE-Q scales hypothesised to contain content relevant to specific gender-affirming treatments. Interviews will elicit new concepts for additional scale development. Each interview will be digitally recorded, transcribed and coded. The main outcome of this phase I study will be the development of a conceptual framework and set of scales to measure outcomes important to evaluating gender-affirming treatments. To this end, analysis will be used to add/drop/revise items of existing scales to achieve content validity. For new concepts, coding will assign top-level domains and themes/subthemes to participant quotes. Codes will be used to develop an item pool to inform scale development. Draft scales will be shown to transgender and gender diverse persons and experts to obtain feedback that will be used to refine and finalise the scales. The field-test version of the GENDER-Q will be translated by following rigorous methods to prepare for the international field-test study. ETHICS AND DISSEMINATION: This study is coordinated at McMaster University (Canada). Ethics board approval was received from the Hamilton Integrated Ethics Board (Canada), the Medical Ethical Committee at VUmc (The Netherlands) and Advarra (USA). Findings will be published in peer-reviewed journals and presented at national and international conferences and meetings. © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: gender-q; lgtbq+; patient-reported outcome; psychometrics; quality of life; transgender
Mesh:
Year: 2018 PMID: 30344182 PMCID: PMC6196938 DOI: 10.1136/bmjopen-2018-025435
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow diagram showing the multiphase mixed methods protocol for developing the GENDER-Q. Reproduced with permission from Wong Riff et al.24 QUAN, quantitative.